Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15430 | 0.86 | CYP3A4 (0.70) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL27741428 | 0.83 | CYP3A4 (0.67) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| Water SCHEMBL28889229 | 0.83 | CYP3A4 (0.67) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| Ammonia Solution, Strong SCHEMBL28239770 | 0.83 | CYP3A4 (0.67) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL17307129 | 0.79 | CYP3A4 (0.56) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL23721668 | 0.78 | CYP3A4 (0.61) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL241534 | 0.78 | CYP3A4 (0.61) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| Cyclohexane SCHEMBL1006843 | 0.78 | CYP3A4 (0.61) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL333217 | 0.78 | CYP3A4 (0.61) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL333218 | 0.78 | CYP3A4 (0.61) | CYP3A4TSHRMAPK1TDP1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5219747-A | Cannabinol derivatives | HOFFMANN-LA ROCHE INC. (US) | 1993-06-15 | — | — | US | claimed |
| US-4833073-A | Immunoassay for tetrahydrocannabinol metabolites | HOFFMANN-LA ROCHE INC. (US) | 1989-05-23 | — | — | US | claimed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-113288888-B | Compounds with vasodilating activity | 烟台邦杰生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115485236-A | Boron-doped carbon material, conductive composition, conductive film, and electricity storage element | 东洋油墨SC控股株式会社 | 2022-12-16 | — | — | CN | disclosed |
| CN-102224127-A | New retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties | SIGMA TAU IND FARMACEUTI | 2011-10-19 | — | — | CN | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| CN-102014914-A | 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as MTOR kinase and PI3 kinase inhibitors, and their syntheses | WYETH CORP | 2011-04-13 | — | — | CN | disclosed |
| US-7741242-B2 | Prepared by crosslinking a homogenized an addition polymer containing units from an unsaturated aryl-containing glycidyl ether or ester and an unsaturated alcohol or carboxylic acid and a zero-valent Pd compound to physically deposit the Pd compound on the polymer; oxidizing alcohols to aldehydes | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-7662977-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1611119-A1 | PI-3 KINASE INHIBITOR PRODRUGS | Semafore Pharmaceuticals, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-6949537-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050203173-A1 | PI-3 kinase inhibitor prodrugs | SIGNALRX PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| EP-1537913-A1 | PALLADIUM CATALYST COMPOSITION | Wako Pure Chemical Industies, Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| EP-1534670-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20040242631-A1 | PI-3 kinase inhibitor prodrugs | SIGNALRX PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004089925-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SEMAFORE PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004020400-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
| EP-0135741-B1 | COATING RESIN COMPOSITION | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | CYP3A4 2794/4885TSHR 562/4885MAPK1 846/4885 |
| US-20050203173-A1 | PI-3 kinase inhibitor prodrugs | PI4KA, PI4KB, PI4K2B | CYP3A4 1187/4885TSHR 3974/4885MAPK1 268/4885 |
| US-20040242631-A1 | PI-3 kinase inhibitor prodrugs | PI4KA, PI4KB, PI4K2B | CYP3A4 1187/4885TSHR 3974/4885MAPK1 268/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | CYP3A4 158/4885TSHR 4770/4885MAPK1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.